Document is current

Article History

Received: 1 December 2019

Accepted: 17 May 2020

First Online: 1 June 2020

Compliance with ethical standards

: The Mayo Clinic Institutional Review Board approved this study and all patients consented to the use of their medical records for research purposes.

: SAP: Research funding has been provided to the institution from Pharmacyclics, MorphoSys, Janssen, AstraZeneca, AbbVie, TG Therapeutics, and Ascentage Pharma for clinical studies in which Sameer A. Parikh is a principal investigator. Sameer A. Parikh has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, Gilead, Verastem Oncology and AbbVie (he was not personally compensated for his participation). NEK: Research funding has been provided to the institution from Pharmacyclics, Acerta, Tolero & MEI Pharma for which Neil E. Kay is a principal investigator. Dr. Kay has also participated as a member of the Data and Safety Monitoring Board for Cytomx Therapeutics, Infinity Pharm, Agios Pharm, Celgene, and MorphoSys. He has also participated in Advisory Board meetings of Pharmacyclics and Janssen. WD: Research funding has been provided to the institution from Merck for which Wei Ding is a principal investigator. SSK: Sponsored Research Funding provided to the laboratory from Novartis, Kite, Actinium, MorphoSys, Lentigen, Humanigen, and Tolero. SSK is inventor on patents licensed to Novartis and Humanigen. SSK is a co-founder of Leah Labs and SensImmune and he has participated as a consultant to Leah Labs and Kiniksa. TDS: Research funding has been provided to the institution from Pharmacyclics, Janssen, Genentech, GlaxoSmithKline, Celgene, Cephalon, and Hospira for which Tait D. Shanafelt is a principal investigator. All other authors have no conflict of interest to report.